TransMedics Reports Third Quarter 2024 Financial Results
Recent Highlights
- Total revenue of
$108.8 million in the third quarter of 2024, a 64% increase compared to the third quarter of 2023 - Generated net income of
$4.2 million or$0.12 per diluted share in the third quarter of 2024 - Owned 18 total aircraft as of
September 30, 2024
"We are proud of our performance year to date and look forward to ending 2024 on a strong note," said
Third Quarter 2024 Financial Results
Total revenue for the third quarter of 2024 was
Gross margin for the third quarter of 2024 was 56%, compared to 61% in the third quarter of 2023. The change from prior year is a result of a higher proportion of service revenue compared to product revenue, which carries a higher margin, in 2024. In addition, we made investments in our NOP network to prepare for future growth.
Operating expenses for the third quarter of 2024 were
Net income for the third quarter of 2024 was
Cash was
2024 Financial Outlook
Webcast and Conference Call Details
The
About
Forward-Looking Statements
This press release contains forward-looking statements with respect to, among other things, our full-year guidance, our growth initiatives and runway, and statements about our operations, financial position, and business plans and our target of achieving 10,000 OCS transplant cases per year in the
Investor Contact:
332-895-3222
Investors@transmedics.com
|
||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||
(in thousands, except share and per share data) |
||||||||
(unaudited) |
||||||||
|
||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
Revenue: |
|
|
|
|
|
|
|
|
Net product revenue |
|
|
|
|
|
|
|
|
Service revenue |
|
42,900 |
|
18,690 |
|
120,998 |
|
36,254 |
Total revenue |
|
108,761 |
|
66,430 |
|
319,916 |
|
160,449 |
Cost of revenue: |
|
|
|
|
|
|
|
|
Cost of net product revenue |
|
13,246 |
|
11,086 |
|
41,800 |
|
26,950 |
Cost of service revenue |
|
34,670 |
|
14,682 |
|
88,048 |
|
27,330 |
Total cost of revenue |
|
47,916 |
|
25,768 |
|
129,848 |
|
54,280 |
Gross profit |
|
60,845 |
|
40,662 |
|
190,068 |
|
106,169 |
|
|
|
|
|
|
|
|
|
Gross margin |
|
56 % |
|
61 % |
|
59 % |
|
66 % |
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research, development and clinical trials |
|
14,266 |
|
11,132 |
|
39,504 |
|
25,294 |
Acquired in-process research and development expenses |
|
— |
|
27,212 |
|
— |
|
27,212 |
Selling, general and administrative |
|
42,656 |
|
30,653 |
|
121,712 |
|
84,993 |
Total operating expenses |
|
56,922 |
|
68,997 |
|
161,216 |
|
137,499 |
Income (loss) from operations |
|
3,923 |
|
(28,335) |
|
28,852 |
|
(31,330) |
Other income (expense): |
|
|
|
|
|
|
|
|
Interest expense |
|
(3,617) |
|
(3,590) |
|
(10,838) |
|
(7,186) |
Interest income and other income (expense) |
|
3,939 |
|
4,996 |
|
10,777 |
|
7,982 |
Total other income (expense), net |
|
322 |
|
1,406 |
|
(61) |
|
796 |
Income (loss) before income taxes |
|
4,245 |
|
(26,929) |
|
28,791 |
|
(30,534) |
(Provision) benefit for income taxes |
|
(29) |
|
1,507 |
|
(184) |
|
1,475 |
Net income (loss) |
|
|
|
|
|
|
|
|
Net income (loss) per share: |
|
|
|
|
|
|
|
|
Basic |
|
|
|
|
|
|
|
|
Diluted |
|
|
|
|
|
|
|
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
Basic |
|
33,441,394 |
|
32,614,059 |
|
33,108,253 |
|
32,474,522 |
Diluted |
|
35,683,952 |
|
32,614,059 |
|
35,218,756 |
|
32,474,522 |
|
||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||
(in thousands) |
||||
(unaudited) |
||||
|
||||
|
|
|
|
|
Assets |
|
|
|
|
Current assets: |
|
|
|
|
Cash |
|
|
|
|
Accounts receivable |
|
90,128 |
|
63,576 |
Inventory |
|
52,152 |
|
44,235 |
Prepaid expenses and other current assets |
|
20,101 |
|
8,031 |
Total current assets |
|
492,475 |
|
510,654 |
Property, plant and equipment, net |
|
271,739 |
|
173,941 |
Operating lease right-of-use assets |
|
6,943 |
|
6,546 |
Restricted cash |
|
500 |
|
500 |
|
|
11,549 |
|
11,990 |
Acquired intangible assets, net |
|
2,202 |
|
2,354 |
Other non-current assets |
|
163 |
|
62 |
Total assets |
|
|
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
Current liabilities: |
|
|
|
|
Accounts payable |
|
|
|
|
Accrued expenses and other current liabilities |
|
42,187 |
|
38,221 |
Deferred revenue |
|
2,184 |
|
1,961 |
Operating lease liabilities |
|
2,543 |
|
2,035 |
Total current liabilities |
|
60,048 |
|
54,934 |
Convertible senior notes, net |
|
449,237 |
|
447,140 |
Long-term debt, net |
|
59,294 |
|
59,064 |
Operating lease liabilities, net of current portion |
|
7,072 |
|
7,707 |
Total liabilities |
|
575,651 |
|
568,845 |
Total stockholders' equity |
|
209,920 |
|
137,202 |
Total liabilities and stockholders' equity |
|
|
|
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-third-quarter-2024-financial-results-302288940.html
SOURCE